SCHEMBL163536

SCHEMBL163536

NC(=O)c1cncc([O])n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.48
TSHR P16473 1/20 0.48
MC4R P32245 1/20 0.48
ADRA1A P35348 1/20 0.48
MC3R P41968 1/20 0.48
LMNA P02545 1/20 0.40
SIRT6 Q8N6T7 3/20 0.38
DGAT1 O75907 3/20 0.36
PIM1 P11309 1/20 0.36
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
SIRT3 Q9NTG7 3/20 0.33
SIRT2 Q8IXJ6 2/20 0.33
SIRT1 Q96EB6 2/20 0.33
LCK P06239 1/20 0.33
F7 P08709 1/20 0.33
F3 P13726 1/20 0.33
SARM1 Q6SZW1 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33
SIRT4 Q9Y6E7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7109264 0.85 TSHR (0.56) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL162261 0.79 HCAR2 (0.46) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL163537 0.77 ADORA3 (0.48) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL3037984 0.77 TSHR (0.54) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL19151399 0.76 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL6377563 0.76 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL13837305 0.76 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL31555012 0.76 SIRT6 (0.50) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL741061 0.76 SIRT6 (0.50) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL3743154 0.76 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 ADORA3 705/4885TSHR 4862/4885MC4R 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.